Abstract
AIMS: Clinical trials have shown that transcatheter aortic valve implantation for aortic stenosis compares favorably to surgical replacement in high-risk patients and is superior to medical therapy in those at prohibitive risk. There is uncertainty however on patterns and trends in transcatheter aortic valve implantation, especially focusing on Italy. METHODS: The RISPEVA study is a prospective Italian registry including 21 institutions. Patients have been enrolled since late 2012, and data collection includes several baseline, procedural, in-hospital, and follow-up details. For the present analysis on patterns and trends, we focused on patients enrolled between 2012 and 2015, and as primary variable on the prevalence of high versus prohibitive surgical risk, limiting our scope to procedural outcomes. RESULTS: A total of 1157 patients were included. The temporal breakdown was 376 (33%) patients enrolled in 2013, 408 (35%) in 2014, and 373 (32%) in 2015. Several patient features differed over time, including risk score, peripheral artery disease, end-stage pulmonary disease, and prior valvuloplasty (all P?<?0.05). Several procedural features differed significantly over time, including sheath size, use of general anesthesia, Prostar closure device, predilation, antiembolic device, new TAVI device, and multiple prostheses (all P?<?0.05). No significant temporal differences were found for major clinical outcomes, whereas the occurrence of moderate or severe postprocedural regurgitation and pacemaker dependency decreased over the years (both P?<?0.05). CONCLUSION: According to the RISPEVA results, the Italian uptake of TAVI is steady, with evident trends toward less invasive approaches and fitter patients.
| Original language | English |
|---|---|
| Journal | Journal of Cardiovascular Medicine |
| DOIs | |
| Publication status | Accepted/In press - Nov 24 2016 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Patterns and trends of transcatheter aortic valve implantation in Italy : insights from RISPEVA. / Giordano, Arturo; Corcione, Nicola; Biondi-Zoccai, Giuseppe; Berti, Sergio; Petronio, Anna Sonia; Pierli, Carlo; Presbitero, Patrizia; Giudice, Pietro; Sardella, Gennaro; Bartorelli, Antonio L.; Bonmassari, Roberto; Indolfi, Ciro; Marchese, Alfredo; Brscic, Elvis; Cremonesi, Alberto; Testa, Luca; Brambilla, Nedy; Bedogni, Francesco.
In: Journal of Cardiovascular Medicine, 24.11.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patterns and trends of transcatheter aortic valve implantation in Italy
T2 - insights from RISPEVA
AU - Giordano, Arturo
AU - Corcione, Nicola
AU - Biondi-Zoccai, Giuseppe
AU - Berti, Sergio
AU - Petronio, Anna Sonia
AU - Pierli, Carlo
AU - Presbitero, Patrizia
AU - Giudice, Pietro
AU - Sardella, Gennaro
AU - Bartorelli, Antonio L.
AU - Bonmassari, Roberto
AU - Indolfi, Ciro
AU - Marchese, Alfredo
AU - Brscic, Elvis
AU - Cremonesi, Alberto
AU - Testa, Luca
AU - Brambilla, Nedy
AU - Bedogni, Francesco
PY - 2016/11/24
Y1 - 2016/11/24
N2 - AIMS: Clinical trials have shown that transcatheter aortic valve implantation for aortic stenosis compares favorably to surgical replacement in high-risk patients and is superior to medical therapy in those at prohibitive risk. There is uncertainty however on patterns and trends in transcatheter aortic valve implantation, especially focusing on Italy. METHODS: The RISPEVA study is a prospective Italian registry including 21 institutions. Patients have been enrolled since late 2012, and data collection includes several baseline, procedural, in-hospital, and follow-up details. For the present analysis on patterns and trends, we focused on patients enrolled between 2012 and 2015, and as primary variable on the prevalence of high versus prohibitive surgical risk, limiting our scope to procedural outcomes. RESULTS: A total of 1157 patients were included. The temporal breakdown was 376 (33%) patients enrolled in 2013, 408 (35%) in 2014, and 373 (32%) in 2015. Several patient features differed over time, including risk score, peripheral artery disease, end-stage pulmonary disease, and prior valvuloplasty (all P?<?0.05). Several procedural features differed significantly over time, including sheath size, use of general anesthesia, Prostar closure device, predilation, antiembolic device, new TAVI device, and multiple prostheses (all P?<?0.05). No significant temporal differences were found for major clinical outcomes, whereas the occurrence of moderate or severe postprocedural regurgitation and pacemaker dependency decreased over the years (both P?<?0.05). CONCLUSION: According to the RISPEVA results, the Italian uptake of TAVI is steady, with evident trends toward less invasive approaches and fitter patients.
AB - AIMS: Clinical trials have shown that transcatheter aortic valve implantation for aortic stenosis compares favorably to surgical replacement in high-risk patients and is superior to medical therapy in those at prohibitive risk. There is uncertainty however on patterns and trends in transcatheter aortic valve implantation, especially focusing on Italy. METHODS: The RISPEVA study is a prospective Italian registry including 21 institutions. Patients have been enrolled since late 2012, and data collection includes several baseline, procedural, in-hospital, and follow-up details. For the present analysis on patterns and trends, we focused on patients enrolled between 2012 and 2015, and as primary variable on the prevalence of high versus prohibitive surgical risk, limiting our scope to procedural outcomes. RESULTS: A total of 1157 patients were included. The temporal breakdown was 376 (33%) patients enrolled in 2013, 408 (35%) in 2014, and 373 (32%) in 2015. Several patient features differed over time, including risk score, peripheral artery disease, end-stage pulmonary disease, and prior valvuloplasty (all P?<?0.05). Several procedural features differed significantly over time, including sheath size, use of general anesthesia, Prostar closure device, predilation, antiembolic device, new TAVI device, and multiple prostheses (all P?<?0.05). No significant temporal differences were found for major clinical outcomes, whereas the occurrence of moderate or severe postprocedural regurgitation and pacemaker dependency decreased over the years (both P?<?0.05). CONCLUSION: According to the RISPEVA results, the Italian uptake of TAVI is steady, with evident trends toward less invasive approaches and fitter patients.
UR - http://www.scopus.com/inward/record.url?scp=85000786897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000786897&partnerID=8YFLogxK
U2 - 10.2459/JCM.0000000000000489
DO - 10.2459/JCM.0000000000000489
M3 - Article
AN - SCOPUS:85000786897
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
ER -